Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle
Trial of Imaging and Schedule in Seminoma Testis
4 other identifiers
interventional
660
1 country
29
Brief Summary
RATIONALE: Imaging procedures, such as MRI and CT scan, may find recurrent cancer. It is not yet known which MRI or CT scan schedule is more effective in finding recurrent cancer. PURPOSE: This randomized phase III trial is comparing four different MRI and CT scan schedules in patients with stage I seminoma of the testicle.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
29 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 25, 2007
CompletedFirst Posted
Study publicly available on registry
January 9, 2008
CompletedStudy Start
First participant enrolled
March 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedAugust 7, 2013
July 1, 2009
8.8 years
December 25, 2007
August 6, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of patients relapsing with Royal Marsden Hospital stage IIC or greater disease
Secondary Outcomes (9)
Difference in mean abdominal mass size at relapse between computed tomography (CT) scan and magnetic resonance imaging (MRI)
Time on surveillance before detection of relapse
Prospective identification of first modality to detect relapse (patient symptom, clinical examination, tumor marker, chest x-ray, cross-sectional image)
Extent of relapse according to International Germ Cell Cancer Collaborative Group classification
Disease-free survival
- +4 more secondary outcomes
Interventions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (29)
Royal Bournemouth Hospital
Bournemouth, England, BH7 7DW, United Kingdom
Sussex Cancer Centre at Royal Sussex County Hospital
Brighton, England, BN2 5BF, United Kingdom
Bristol Haematology and Oncology Centre
Bristol, England, BS2 8ED, United Kingdom
Addenbrooke's Hospital
Cambridge, England, CB2 2QQ, United Kingdom
Gloucestershire Oncology Centre at Cheltenham General Hospital
Cheltenham, England, GL53 7AN, United Kingdom
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, HD3 3EA, United Kingdom
Leeds Cancer Centre at St. James's University Hospital
Leeds, England, LS9 7TF, United Kingdom
Leicester Royal Infirmary
Leicester, England, LE1 5WW, United Kingdom
Lincoln County Hospital
Lincoln, England, LN2 5QY, United Kingdom
UCL Cancer Institute
London, England, NW3 2QG, United Kingdom
Charing Cross Hospital
London, England, W6 8RF, United Kingdom
University College of London Hospitals
London, England, WIT 3AA, United Kingdom
Mid Kent Oncology Centre at Maidstone Hospital
Maidstone, England, ME16 9QQ, United Kingdom
Christie Hospital
Manchester, England, M20 4BX, United Kingdom
James Cook University Hospital
Middlesbrough, England, TS4 3BW, United Kingdom
Northern Centre for Cancer Treatment at Newcastle General Hospital
Newcastle upon Tyne, England, NE4 6BE, United Kingdom
Northampton General Hospital
Northampton, England, NN1 5BD, United Kingdom
Mount Vernon Cancer Centre at Mount Vernon Hospital
Northwood, England, HA6 2RN, United Kingdom
Nottingham City Hospital
Nottingham, England, NG5 1PB, United Kingdom
Churchill Hospital
Oxford, England, OX3 7LJ, United Kingdom
Berkshire Cancer Centre at Royal Berkshire Hospital
Reading, England, RG1 5AN, United Kingdom
Cancer Research Centre at Weston Park Hospital
Sheffield, England, S1O 2SJ, United Kingdom
Royal Marsden - Surrey
Sutton, England, SM2 5PT, United Kingdom
Yeovil District Hospital
Yeovil, England, BA21 4AT, United Kingdom
Centre for Cancer Research and Cell Biology at Queen's University Belfast
Belfast, Northern Ireland, BT9 7BL, United Kingdom
Aberdeen Royal Infirmary
Aberdeen, Scotland, AB25 2ZN, United Kingdom
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, G11 6NT, United Kingdom
Velindre Cancer Center at Velindre Hospital
Cardiff, Wales, CF14 2TL, United Kingdom
Glan Clwyd Hospital
Rhyl, Denbighshire, Wales, LL 18 5UJ, United Kingdom
Related Publications (1)
Joffe JK, Cafferty FH, Murphy L, Rustin GJS, Sohaib SA, Gabe R, Stenning SP, James E, Noor D, Wade S, Schiavone F, Swift S, Dunwoodie E, Hall M, Sharma A, Braybrooke J, Shamash J, Logue J, Taylor HH, Hennig I, White J, Rudman S, Worlding J, Bloomfield D, Faust G, Glen H, Jones R, Seckl M, MacDonald G, Sreenivasan T, Kumar S, Protheroe A, Venkitaraman R, Mazhar D, Coyle V, Highley M, Geldart T, Laing R, Kaplan RS, Huddart RA; TRISST Trial Management Group and Investigators. Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). J Clin Oncol. 2022 Aug 1;40(22):2468-2478. doi: 10.1200/JCO.21.01199. Epub 2022 Mar 17.
PMID: 35298280DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Johnathan Joffe, MD
Huddersfield Royal Infirmary
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
December 25, 2007
First Posted
January 9, 2008
Study Start
March 1, 2008
Primary Completion
December 1, 2016
Last Updated
August 7, 2013
Record last verified: 2009-07